Succinate dehydrogenase B gene mutations predict survival in patients with malignant pheochromocytomas or paragangliomas - PubMed (original) (raw)
. 2007 Oct;92(10):3822-8.
doi: 10.1210/jc.2007-0709. Epub 2007 Jul 24.
Affiliations
- PMID: 17652212
- DOI: 10.1210/jc.2007-0709
Succinate dehydrogenase B gene mutations predict survival in patients with malignant pheochromocytomas or paragangliomas
Laurence Amar et al. J Clin Endocrinol Metab. 2007 Oct.
Abstract
Context: Pheochromocytomas and paragangliomas may be malignant either at presentation or during recurrence, but the clinical course of malignant tumors is unpredictable.
Objective: The objective was to analyze survival according to clinical characteristics at diagnosis of malignancy and the presence or absence of SDHB mutations.
Design: This was a retrospective cohort study.
Setting and participants: A total of 54 patients with malignant tumors were included. Malignancy was scored according to the presence of metastases or histologically documented lymph node invasion.
Main outcome measures: The main outcome was the specific survival after the diagnosis of the first metastasis.
Results: Germline mutations were identified in SDHB (n = 23, including 21 patients with apparent sporadic tumors) and VHL (n = 1) genes, and two patients had neurofibromatosis 1. Patients were followed up from the diagnosis of primary tumor and from the diagnosis of the first metastasis to the present or to death with medians of 79 [interquartile range (IQR) 24; 190] and 39 [IQR 14; 94] months, respectively. The 5-yr probability of survival after the diagnosis of the first metastasis was 0.55 (95% confidence interval 0.39-0.69). Patients with SDHB mutations were younger, more frequently had extra-adrenal tumors, and had a shorter metanephrine excretion doubling time. The presence of SDHB mutations was significantly and independently associated with mortality (relative risk 2.7; 95% confidence interval 1.2, 6.4; P = 0.021).
Conclusion: SDHB mutations, frequent in patients with malignant pheochromocytomas or paragangliomas, are associated with shorter survival. Therefore, SDHB genetic testing may be of prognostic value for such patients, even those with an apparent sporadic and/or benign presentation at diagnosis.
Similar articles
- Germline SDHB mutations are common in patients with apparently sporadic sympathetic paragangliomas.
Klein RD, Jin L, Rumilla K, Young WF Jr, Lloyd RV. Klein RD, et al. Diagn Mol Pathol. 2008 Jun;17(2):94-100. doi: 10.1097/PDM.0b013e318150d67c. Diagn Mol Pathol. 2008. PMID: 18382370 - SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma.
Hadoux J, Favier J, Scoazec JY, Leboulleux S, Al Ghuzlan A, Caramella C, Déandreis D, Borget I, Loriot C, Chougnet C, Letouzé E, Young J, Amar L, Bertherat J, Libé R, Dumont F, Deschamps F, Schlumberger M, Gimenez-Roqueplo AP, Baudin E. Hadoux J, et al. Int J Cancer. 2014 Dec 1;135(11):2711-20. doi: 10.1002/ijc.28913. Epub 2014 May 5. Int J Cancer. 2014. PMID: 24752622 - Clinical presentation and penetrance of pheochromocytoma/paraganglioma syndromes.
Benn DE, Gimenez-Roqueplo AP, Reilly JR, Bertherat J, Burgess J, Byth K, Croxson M, Dahia PL, Elston M, Gimm O, Henley D, Herman P, Murday V, Niccoli-Sire P, Pasieka JL, Rohmer V, Tucker K, Jeunemaitre X, Marsh DJ, Plouin PF, Robinson BG. Benn DE, et al. J Clin Endocrinol Metab. 2006 Mar;91(3):827-36. doi: 10.1210/jc.2005-1862. Epub 2005 Nov 29. J Clin Endocrinol Metab. 2006. PMID: 16317055 - Review: Should patients with apparently sporadic pheochromocytomas or paragangliomas be screened for hereditary syndromes?
Jiménez C, Cote G, Arnold A, Gagel RF. Jiménez C, et al. J Clin Endocrinol Metab. 2006 Aug;91(8):2851-8. doi: 10.1210/jc.2005-2178. Epub 2006 May 30. J Clin Endocrinol Metab. 2006. PMID: 16735498 Review. - Succinate-Dehydrogenase Deficient Paragangliomas/Pheochromocytomas: Genetics, Clinical Aspects and Mini- Review.
Rusyn L, Kohn B. Rusyn L, et al. Pediatr Endocrinol Rev. 2017 Mar;14(3):312-325. doi: 10.17458/per.vol14.2017.RK.succinatedehydrogenase. Pediatr Endocrinol Rev. 2017. PMID: 28508602 Review. No abstract available.
Cited by
- Heritable Cancer Syndromes Related to the Hypoxia Pathway.
Henegan JC Jr, Gomez CR. Henegan JC Jr, et al. Front Oncol. 2016 Mar 22;6:68. doi: 10.3389/fonc.2016.00068. eCollection 2016. Front Oncol. 2016. PMID: 27047799 Free PMC article. Review. - 15 YEARS OF PARAGANGLIOMA: Clinical manifestations of paraganglioma syndromes types 1-5.
Benn DE, Robinson BG, Clifton-Bligh RJ. Benn DE, et al. Endocr Relat Cancer. 2015 Aug;22(4):T91-103. doi: 10.1530/ERC-15-0268. Endocr Relat Cancer. 2015. PMID: 26273102 Free PMC article. Review. - Mutational profile and genotype/phenotype correlation of non-familial pheochromocytoma and paraganglioma.
Albattal S, Alswailem M, Moria Y, Al-Hindi H, Dasouki M, Abouelhoda M, Alkhail HA, Alsuhaibani E, Alzahrani AS. Albattal S, et al. Oncotarget. 2019 Oct 15;10(57):5919-5931. doi: 10.18632/oncotarget.27194. eCollection 2019 Oct 15. Oncotarget. 2019. PMID: 31666924 Free PMC article. - Succinate detection using in vivo 1H-MR spectroscopy identifies germline and somatic SDHx mutations in paragangliomas.
Lussey-Lepoutre C, Bellucci A, Burnichon N, Amar L, Buffet A, Drossart T, Fontaine S, Clement O, Benit P, Rustin P, Groussin L, Meatchi T, Gimenez-Roqueplo AP, Tavitian B, Favier J. Lussey-Lepoutre C, et al. Eur J Nucl Med Mol Imaging. 2020 Jun;47(6):1510-1517. doi: 10.1007/s00259-019-04633-9. Epub 2019 Dec 13. Eur J Nucl Med Mol Imaging. 2020. PMID: 31834447 - New Insights on the Genetics of Pheochromocytoma and Paraganglioma and Its Clinical Implications.
Jhawar S, Arakawa Y, Kumar S, Varghese D, Kim YS, Roper N, Elloumi F, Pommier Y, Pacak K, Del Rivero J. Jhawar S, et al. Cancers (Basel). 2022 Jan 25;14(3):594. doi: 10.3390/cancers14030594. Cancers (Basel). 2022. PMID: 35158861 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials